Halda Therapeutics Garners $126 Million in Series B Extension to Propel Innovative Cancer Treatments into Clinical Trials
Halda Therapeutics, a leading biotechnology firm renowned for its pioneering cancer therapies, has successfully raised $126 million in a Series B extension. This latest funding round saw significant participation from premier investors, including Deep Track Capital, Frazier Life Sciences, RA Capital Management, Vida Ventures, Boxer Capital, and Taiho Ventures. Existing backers such as Canaan Partners,…